HPV VACCINATION PROGRAMMES- HOW EFFICIENT AND SAFE
Accepted
29 March 2026
Available Online
20 July 2019
Abstract
THE PURPOSE OF THIS PAPER IS TO ASSESS THE DATA CURRENTLY AVAILABLE IN LITERATURE REGARDING THE EFFECTIVENESS AND HARMS OF HPV VACCINATION PROGRAMMES. THERE ARE NOW MORE THAN FIFTEEN COUNTRIES WHICH HAVE DATA REGARDING VACCINE EFFECTIVENESS AND SHOW FALLS IN TARGETED TYPES FOLLOWING VACCINATION. THERE ARE CURRENT LY THREE FDA - APPROVED MULTIVALENT PROHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES AND ALTHOUGH THERE IS RIGUROUS PROOF OF THE NEED FOR IMPLEMENTING VACCINATION NATIONAL SCHEDULES, CONCERNS REGARDING THEIR SAFETY CONTINUE TO EMERGE.
Keywords
HPV VACCINATION
EFFECTIVENESS
SAFETY
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Walboomers, JM; Jacobs, MV; Manos, MM; et al. Human papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189 (1):12-9.
[2]
Mehedintu, C; Plotogea, M; Antonovici, M; Todea, C . The human papillomavirus infection. Dermato Venerol 2013;58:277-86.
[3]
Tataru, AL; Furau, G; Afilon, J; Ionescu, C; Dimitriu, M; Bratu, OG; Tit, DM; Bungau, S; Furau, C. The situation of cervical cancers in the context of female genital cancer clustering and burden of disease in Arad County, Romania. J. Clin. Med. 2019, 8(1), E96.
[4]
Sinescu, RD; Niculae, A; Peride, I; Vasilescu, F; Bratu, OG; Mischianu, DL; Jinga, M; Checheriţă, IA. Uterus neuroendocrine tumor - a severe prognostic factor in a female patient with alcoholic cirrhosis undergoing chronic hemodialysis. Rom J Morphol Embryol. 2015; 56(2):601-605.
[5]
Cozma, CN; Raducu, L; Avino, A; Scaunasu, RV; Bratu, O; Marcu, DR; Jecan, CR . A rare case of vulvar squamos cell carcinoma; case presentation. Journal of Clinical and Investigative Surgery, 2018, 3(1): 32-36.
[6]
Dimitriu, MCT; Ionescu, CA; Gheorghiu, DC; Socea, LI; Bratu, OG; Constantin, VD; Ples, L; Neacsu, A; Bobic, S; Socea, B . Mepivacaine hydrochloride - an efficient local anesthetic solution for the electroresection of the benign and preneoplastic lesi ons of the cervix and uterus . Rev Chim (Bucharest), 2018, 69(9): 2391-2395.
[7]
Stanescu, AMA; Grajdeanu, IV; Iancu, MA; Stefani, C; Serban, B; Bratu, OG; Socea, B; Diaconu, CC. Condylomata acuminata and Candida vulvovaginitis during pregnancy – current facts and therapeutic possibilities. Romanian Medical Journal, 2019, LXVI(2): 119
[8]
Spinu, D; Radulescu, A; Iatagan, C; Popescu, R; Madan, V; Bratu, O; Ranetti, AE; Mischianu, D . Bilateral inguinoscrotal Buschke -Lowenstein disease-a case report . Revista Română de Urologie, 2013, 12(1): 41-43.
[9]
Spinu, D; Mischianu, D; Bratu, O; Aungurenci, A; Manache, S; Ciuca, A. HPV implications in benign prostatic impairments-a literature review. Modern Medicine, 2014, 21(4): 298-303
[10]
Spinu, D; Radulescu, A; Bratu , O; Checherita, IA; Ranetti, AE; Mischianu, D . Giant condyloma acuminatum - Buschke-Lowenstein disease - a literature review. Chirurgia, 2014, 109(4): 445-450.
[11]
Spinu, D; Bratu, O; Oprea, I; Marc u, D; Mischianu, D . Human papilloma virus infection in men - topographical and procedural aspects-a systematic review. Revista Română de Urologie, 2016, 15(4): 23 - 27.
[12]
Spinu, D; Bratu, O; Marcu, D; Niculae, A; Geavlete, B; Diaconu, C; Mischianu, D . HPV and bladder cancer-is there a connection?. Modern Medicine, 2017, 24(1): 1-4.
[13]
Bosch, FX; Lori ncz, A; Munoz, N; Meijer, CJLM; Shah, KVS . The causal relation between human papilloma virus and cervical cancer. J Clin Pathol 2002;55(4): 244-65.
[14]
Lowy, DR. HPV vaccination top revent cervical cancer and other HPV - associated disease: from basic science to effective interventions. J Clin Invest 2016;126(1): 5-11.
[15]
Mehedintu, C; Bratila, E; Cirstoiu, M; et al. A fixed herbal combination- a new approach in HPV cervical infection treatment. Farmacia 2018;66(3):502-6.
[16]
Global Cancer Observatory, Cancer Tomorrow: https://gco.iarc.fr/tomorrow/home.
[17]
https://www.iarc.fr/wp-content/uploads/2019/02/pr264_E.pdf
[18]
Wang, CJ; Palefsky, JM. Human papillomavirus (HPV) infections and the importance of HPV vaccination. Curr Epidemiol Rep 2015;2(2): 101-9.
[19]
Kessels, SJM; et al . Factors associated with HPV vaccine uptake in teenage girls: a systematic review . Vaccine 2012;30(24):3546-56.
[20]
https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet
[21]
Skinner, SR; Cooper Robbins, SC. Voluntary school-based human papillomavirus vaccination: an efficient and acceptable model for achieving high vaccine coverage in adolescents. J Adolesc Health 2010;47(3):215- 8.
[22]
Penta, MA; Baban, A. Mass media coverage of HPV vaccination in Romania: a content analy sis. Health Educ Res 2014;29(6):977-92.
[23]
Harro, CD; Pang, YY; Roden, RB; et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2011;93(4):284-92.
[24]
Lehtinen, M; Paavonen, J; Wheeler, CM; et al. Overall efficacy of HPV- 16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised , double-blind PATRICIA trial. Lancet Oncol 2012;13(1):88-9.
[25]
Paavonen, J; Naud, P; Salmeron , J; et al . Efficacy of human papillomavirus (HPV) - 16/18 AS04 - adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
[26]
Hildesheim, A; Herrero, R; Wacholder, S; et al. Effect of human papillomavirus 16/18 LI viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53.
[27]
Kjaer, SK; Sigurdsson, K; Iversen, OE; et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high -grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2:868-78.
[28]
Group, FIIS; Dillner, J; Kjaer, SK; et al. Four y ear efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493.
[29]
Palefsky, JM; Giuliano, AR; Goldstone, S ; et al . HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365(17):1576-85.
[30]
https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf Accessed on 17th June.
[31]
Huh, WK; Joura, EA; Giuliano, AR; et al. Final efficacy, immunogenicity, and safety analyses of a nine- valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet 2017;390(10108):2143-59.
[32]
Kjaer, SK; Nygard, M; Dillner, J; et al . A 12 -year follow -up on the long -term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clin Infect Dis 2018;66(3):339-45.
[33]
Joura, EA; Giuliano, AR; Iversen, OE; et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372(8):711-23.
[34]
Vesikari, T; Brodszki, N; van Damme, P; et al . A randomized, double -blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil in 9-15-year-old girls. Pediatr Infect Dis J 2015;34(9):992-8.
[35]
Xu, L; Simoens, C; Martin -Hirsch, P; Arbyn, M . Prophylactic vacci nation against human papillomaviruses to prevent cervical cancer and its precursors . Cochrane Database Syst Rev 2018;2018(5):CD009069.
[36]
Guevara, AM; Suarez, E; Victoria, A; et al . Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine. Hum Vaccin Immunother 2019;15(1):141-5.
[37]
Berceanu, C; Bratila, E; Cirstoiu, M; et al. Colposcopic assessment and management of HPV infection in pregnancy. Ginecologia. Ro 2016;14(4):6-12.
[38]
Markowitz, LE; Drolet, M; Perez, N; Jit, M; Brisson, M. Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs . Vaccine 2018;32:4806- 15.
[39]
Tan, N; Monisha, S; Winer, R; et al. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa. Vaccine 2018;36(32 Pt A):4830-6.
[40]
Arnheim-Dahlstrom, L; Pasternak, B; Svanstrom, H; Sparen, P; Hviid, A . Autoimmune, neurological, and venous thrombembolic adverse events after immunisation of adolescent girls with quadriv alent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013;347:f5906.
[41]
Ruiz-Sternberg, AM; Moreira, ED Jr; Restrepo, JA; et al . Efficacy, immunogenicity, and safety of 9 - valent human papillomavirus in Latin American girls, boys and you ng women . Papillomavirus Res 2018;5:63-74.
[42]
Schilling, A; Parra, MM; Gutierrez, M; et al . Coadministration of a 9 -valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics 2015;136(3):e563-72.
[43]
Stanculescu, R; Ceausu, M; Ceausu, Z; Bausic, V. Immunofluorescence expression of Ki -67, p53,and cyclin inhibitors (p16 ink4a, p21 and p27) in low -grade cervical lesions versus high -grade cervical lesions. Research study on cell cultures. Rom J Morphol Embryol 2013;54(3 Suppl):725-34.
[44]
Stanculescu, R; Bratila, E; Bausic, V; Vladescu, T. The triage of low-grade cytological abnormalities by the immunocytological expression of cyclin-dependent kinase inhibitor p16INK4a versus human papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+. Rom J Morphol Embryol 2013;54(4):1061-5.
[45]
Berceanu, C; Paitici, S; Berceanu, S; Bratila, E; et al. Colposcopic, histologic and immunohistochemical assessment in cervical intraepithelial lesions. Rev Chim 2018; 69(8):2245-50.
[46]
Signorelli, C; Odone, A; Ciorba, A; et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect 2017;145(10):1962-82.
[47]
Kavanagh, K; Pollock, K G; Cuschieri, K; et al . Changes in the pr evalence of human papillomavirs following a national bivalent human papillomavirus vaccination programme in Scotland: a 7 -year cross- sectional study. Lancet Infect Dis 2017;17(12):1293-1302.